Search Medical Condition
Please enter condition
Please choose location from dropdown

Tupelo, Mississippi Clinical Trials

A listing of Tupelo, Mississippi clinical trials actively recruiting patient volunteers.

RESULTS

Found (41) clinical trials

Evaluation of Major Cardiovascular Events in Patients With or at High Risk for Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

Phase

0.0 miles

Learn More »

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency

This is a double-blind, multicenter, prospective, randomized, placebo-controlled study to assess the effects of IV FCM compared to placebo on the 12-month rate of death, hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test (6MWT) for patients in heart failure with iron deficiency. After an ...

Phase

0.0 miles

Learn More »

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

The study consists of a screening visit, a wash out period of up to 3 weeks, when existing phosphate lowering medication is withheld, an 8-week treatment period, in which all groups receive tenapanor, and a 4-week placebo-controlled, randomized withdrawal period, during which patients are re-randomized 1:1 to either remain on ...

Phase

0.0 miles

Learn More »

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ) Compared to Placebo and Adalimumab in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

The goal of this Phase III study is to assess the safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who have responded inadequately to MTX. The primary endpoint of the trial is at Week 12. Olokizumab is expected to reduce the disease activity and ...

Phase

0.0 miles

Learn More »

Prospective Outcomes Study: Vectra DA Guided Care Compared to Usual Care

To determine whether a strategy of Vectra DA guided care (Arm A), compared with usual care (Arm B), achieves non-inferior clinical outcomes while reducing the cost of treatment in patients with active RA and an inadequate response to MTX monotherapy.

Phase N/A

0.0 miles

Learn More »

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

This is an observational, multicenter study in patients treated with nivolumab for the approved indications of melanoma and lung cancer in Australia, the EU, Switzerland, and the United States (US). Targeted countries in the EU for study participation include Austria, Belgium, France, Germany, Italy, Spain, and the United Kingdom (UK). ...

Phase N/A

0.0 miles

Learn More »

SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the absence of antihypertensive medications.

Phase N/A

0.0 miles

Learn More »

SPYRAL HTN-ON MED Study

The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.

Phase N/A

0.0 miles

Learn More »

Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor

The aim of this study is to determine if the Investigational Medicinal Product Tedopi (OSE2101) is more effective than standard treatment in treating patients with stage IIIB NSCLC unsuitable for radiotherapy or metastatic NSCLC in second- or third-line treatment after failure of immune checkpoint-inhibitor regimens.

Phase

0.0 miles

Learn More »

Evaluation of the Long Term Safety Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ) in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1 2 or 3.

The goal of this Phase III study is to evaluate the long-term safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who previously completed 24 weeks of double-blind treatment with OKZ in the core studies. OKZ is expected to reduce the disease activity and induce ...

Phase

0.0 miles

Learn More »